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Objectives: To contribute to a precise and thorough knowledge of immune-related
adverse events (irAE) induced by immune checkpoint inhibitors (ICI) and to emphasize
the importance of this specific form of toxicity in terms of potential predictive value and
long-term effects.
Materials and Methods: We report the first case of granulomatosis with polyangiitis
(GPA) in a patient treated with an anti-Programmed Death protein-1 (PD-1) antibody for
advanced non-small-cell lung cancer (NSCLC).
Results: After a single dose of this drug the patient showed severe myositis associated
with a high anti-PR3 anti-neutrophil cytoplasmic antibody titer. Discontinuation of the
anti-PD-1 and introduction of corticoids led to a remission of the irAE. Regarding tumor
a partial response was noted. A year later a neutrophilic, sterile pleural exudate and
cutaneous lesions appeared with the pathological findings of neutrophilic vasculitis.
Retreatment with corticoids induced a new remission of symptoms. It remains unclear
whether GPA was preexisting and clinically silent but revealed by the use of ICI or
primarily induced by this treatment. Conclusions: irAE are rare when anti-PD-1 antibodies
are used in monotherapy. They present with a distinct clinical picture and temporal
course and require specific treatment. Patients with irAE usually have a favorable
oncological outcome.
Keywords: immune checkpoint inhibitor, non-small-cell lung cancer, granulomatosis with polyangiitis, immune-
related adverse events, anti-PD-1 antibody
INTRODUCTION
Immune-checkpoint inhibitors (ICI) have become widely used in advanced non-small-cell lung
cancer (NSCLC). Classically, patients with preexisting autoimmune disorder (PAID) have been
excluded from clinical trials using ICI. Real-life experience, however, shows that physicians
sometimes do prescribe ICI to those patients (1, 2). Although mostly well-tolerated, ICI can cause
severe and irreversible immune-related adverse events (irAE), affecting the quality of life and
further lines of treatment. Timely recognition of irAE is paramount in order to control them.
Sibille et al. Pembrolizumab-Induced Granulomatosis With Polyangiitis
We report the case of a patient with advanced NSCLC in
whom treatment with pembrolizumab revealed a granulomatosis
with polyangiitis (GPA). We then discuss the predictive value of
irAE and safety of ICI in patients with PAID.
CASE PRESENTATION
A 64-years old male patient was diagnosed with stage IVB
poorly differentiated NSCLC favoring adenocarcinoma of the
right upper lobe with several bone lesions (cT4N2M1c). His
medical history included a cerebrovascular accident and ischemic
heart disease with subacute myocardial infarction in 2003. His
chronic medication included acetylsalicylate acid 100mg once
daily (OD) and simvastatin 40mg 0D, both since 2003. Regarding
the tumor no driver mutation was identified by next-generation
sequencing analysis. The Programmed Death Ligand-1 (PD-L1)
expression level was assessed by immunohistochemistry using
a monoclonal antibody to PD-L1 (clone 22C3, Dako) and a
Benchmark Ultra (Roche) automated scope with subsequent
evaluation by a certified pathologist, revealing 100% staining
of a section including at least 100 evaluable tumor cells.
Hence, pembrolizumab 200mg every 3 weeks was started.
Ten days after the first dose the patient was admitted to
the hospital due to severe myalgia in both lower limbs with
severe functional loss. Biochemistry showed creatine kinase
(CK) of 1265 IU/L (upper limit of normal (ULN) = 190)
and myoglobin of 2361 µg/L (ULN = 72) with normal renal
function. Autoimmune serology showed a normal anti-nuclear
factor (ANF) titer (1/80) without any characterization (especially
for primary immune-mediated myositis with no anti-JO1, PL-7,
PL-12, EJ, SRP, Mi-2, MDA-5, HMGCoA reductase) and anti-
neutrophil cytoplasmic antibodies (ANCA) with a high titer
of anti-PR3 (178 U/mL, ULN = 2); the infectious serology
was negative. The statin was taken for several years prior to
these symptoms and CK level before the start of the anti-PD-
1 was normal. The electroneuromyography before corticoids
showed proximal myopathy of moderate intensity without
signs of necrosis. The quadriceps biopsy before corticotherapy
was normal. He was treated with analgesics, intravenous
fluids, and high-dose methylprednisolone (1 mg/kg/day) with
favorable evolution. The diagnosis of immune-mediated myositis
associated to granulomatosis with polyangiitis (GPA), former
Wegener’s disease, was established. The anti-PD-1 remained
discontinued. Eight months after an initial partial response (PR)
to pembrolizumab, progressive disease was noted and second-
line doublet chemotherapy was started after antalgic irradiation
of a metastatic pelvic mass. Subsequently, PR was noted. A year
after the initial presentation of myositis the patient’s condition
worsened due to dyspnea and arthritis. Evaluation showed a new
left-sided pleural effusion and a new lung consolidation. Based
on a strong inflammatory syndrome (C-reactive protein (CRP)
116 mg/dL) and a neutrophilic exudate without evidence for
empyema the patient was treated with amoxicilline-clavulanate
for 14 days. In total, three pleural fluid cultures remained
sterile. Due to persistence of the effusion and lack of clinical
improvement a pleuroscopy was performed. The fluid appeared
unclear and a few non-specific lesions were biopsied on the
parietal pleura. They revealed a subacute pleuritis without
tumor infiltration, granuloma or vasculitis. The arthritis was
symmetrical and located in the wrists, metacarpophalangeal
(MCP) joints and knees, without any evidence for infection or
crystal-associated disease. A few days later, skin lesions appeared
on the MCP and knees (Figure 1). Biopsy there showed a
neutrophilic vasculitis, as can be seen in cutaneous forms of
GPA (3) (Figure 2). The new lung consolidation was biopsied
and showed only necrosis with no specific features of GPA-
related lung involvement. Along with this clinical deterioration
the autoimmune serology showed a rise in anti-PR3 titer
(352.1 U/mL). The CRP dropped dramatically after initiation of
corticoids (methylprednisolone at 1 mg/kg/day) along with clear
clinical improvement. Recent clinical and radiological evaluation
showed that the patient was in good overall condition with no
signs of oncological progression despite discontinuation of the
chemotherapy. We noted a progression-free survival (PFS) of
10 months after the second line chemotherapy and an overall
survival (OS) of 18 months.
DISCUSSION
With this case we report a unique and rare but severe side effect
of pembrolizumab with long-lasting consequences in a NSCLC
FIGURE 1 | Dark red, necrotic, slightly tender lesions developed symmetrically
on MCP joints and knees.
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FIGURE 2 | Hematoxylin and eosin (HE) staining shows blood vessels (white
areas) with surrounding neutrophilic inflammatory aggregates (arrows),
establishing the diagnosis of neutrophilic vasculitis. Picture magnification: 20x;
scale bar: 50µ.
patient. It remains uncertain whether GPA was preexisting and
clinically silent but revealed by the use of the anti-PD-1 or
primarily induced by this treatment. Indeed, no autoimmune
serology was available from before the start of treatment.
Retrospectively, the patient mentionedmild myalgia with normal
CK values prior to diagnosis and treatment, responding to
corticoids. We therefore think they were possibly signs of a low
active GPA.
Immune-related adverse events (irAE) are a kind of adverse
events specific to immune checkpoint inhibitors (ICI). Virtually
all organs can be affected depicting a wide variety of
symptoms. They mostly appear early during treatment but
can also appear long after drug discontinuation. Relapses
are possible, also in the long term, as seen in our patient
(4). Severe irAE occur at a low frequency (∼10%) for
anti-PD-1/-PD-L1 used in monotherapy (5–9). The general
consensus for their management is high-dose corticoids and
interruption of the ICI. In the absence of response, adding
immunomodulators (mycophenolate mofetyl, anti-TNFα) is
recommended (4, 10).
Beside their impact on patients’ quality of life and treatment
plan, irAE are of specific interest for the clinician. They are
considered potential predictors of response to treatment. In
NSCLC, several studies showed superior PFS, response rates
(RR) and/or OS in patients treated with anti-PD-1/anti-PD-L1
and showing irAE of various types and severity (11–13). The
responses were independent of corticoids when needed. These
series are, however, small-sized and retrospective. Our patient’s
tumor showed a PR according to the REsponse Criteria in Solid
Tumors (RECIST) version 1.1 with a 50% reduction in the sum
of target lesions and a PFS of 8 months after a single dose
of pembrolizumab.
Mechanisms of irAE are not yet fully understood. In
melanoma, it is argued that there exists a similarity between
self-antigens and tumor neoantigens (14). Due to checkpoint
inhibition, reactivated and expanding T-cells can interact with
both tumor and healthy cells. Preexisting autoimmunity can
also explain irAE: preexisting inactivated T-cells directed at self-
antigens get reactivated by ICI, clinically translating into irAE
(15). ICI might also impact B-cells, either directly via the PD-1
receptor or via the action of T-cells. These effects, however, are
not yet fully understood (16).
New onset granulomatous diseases have been described in
cancer patients treated with ICI (17, 18). These cases were
involving the lungs and/or lymph nodes and pathologically
identified as sarcoid-like reactions. To our knowledge, only one
case of ICI-induced GPA has been reported in a melanoma
patient first treated with ipilimumab, then with pembrolizumab
(19). As CD4+ T-cells driven disease, it is understandable that
sarcoidosis may be revealed by ICI that will increase the CD4+ T
lymphocyte population although the precise mechanisms of this
have not been ascertained so far. Wilde et al. suggested the role of
the negative coregulatory factor PD-1 in GPA by demonstrating
a high level of PD-1 expression in a series of 32 patients as
compared to healthy controls and the lack of PD-1 on CD4+
lymphocytes in GPA lesions (20). The IL-17 pathway, known
to induce inflammatory and autoimmune phenomena, is also
suspected to play a role in GPA as levels of IL-17 producing T
cells (Th17) were found to be increased, irrespective of disease
activity (21).
Classically, patients known to have an autoimmune disorder
have been excluded from clinical trials with ICI. Daily practice,
however, shows that this restriction is not always followed. Small-
sized studies of such (mainly melanoma) patients treated with
an anti-PD-1 are available (1, 2). Reporting on mostly stable
PAID, both studies show an increased risk of (new) autoimmune
symptoms in ∼40% of patients, mainly with low-grade severity.
The permanent discontinuation rate due to irAE was 8% (1) vs.
9% (2) which is similar to patients with no PAID (5–9). The type
of PAID might also indicate a higher vs. lower risk of flare on
anti-PD-1 treatment, as is the case for rheumatologic disorders,
closely linked to the PD-1/PD-L1 axis (1). Danlos et al. found an
earlier onset of irAE in patients with PAID compared to patients
without PAID (2). Both studies found a similar efficacy of ICI in
patients with and without PAID on anti-PD-1 in terms of OS and
RR. As a consequence, both authors conclude that ICI treatment
in patients with PAID is feasible, albeit requiring adequate follow-
up and multidisciplinary management. Systematic autoimmune
screening before the start of ICI might reinforce the awareness
for irAE.
CONCLUSION
ICI are commonly used in the treatment of advanced NSCLC.
They can, although rarely, induce severe irAE that can cause
a major morbidity with potentially long-term effects and that
can impact further treatment plan. We describe the first case
of GPA in a patient treated with an anti-PD-1 antibody for
advanced NSCLC. Although stable PAID does not seem an
absolute contraindication to the use of ICI, close monitoring for
side effects in these patients seems warranted. Patients presenting
an irAE seem to have a favorable oncological outcome. The exact
mechanisms of irAE remain unclear.
Frontiers in Oncology | www.frontiersin.org 3 June 2019 | Volume 9 | Article 478
Sibille et al. Pembrolizumab-Induced Granulomatosis With Polyangiitis
PATIENT INFORMED CONSENT
Written informed consent was obtained from the participant
for the publication of this case report and any potentially
identifying images/information.
AUTHOR CONTRIBUTIONS
AS reviewed the literature and wrote the paper. RA and MP
followed the patient and collected clinical and biological data.
OM analyzed the autoimmune serology data and contributed
to the redaction of the manuscript. ND gave the pathology
input of this case. RL and BD reviewed and contributed to the
final version of the paper. All authors read and approved the
final manuscript.
FUNDING
This research did not receive any specific grant from funding
agencies in the public, commercial, or non-profit sector.
REFERENCES
1. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG,Wong ANM, Park JJ,
et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting
autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. (2017)
28:368–76. doi: 10.1093/annonc/mdw443
2. Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. Safety
and efficacy of anti-programmed death 1 antibodies in patients with cancer
and pre-existing autoimmune or inflammatory disease. Eur J Cancer. (2018)
91:21–9. doi: 10.1016/j.ejca.2017.12.008
3. Comfere NI, Macaron NC, Gibson LE. Cutaneous manifestations of
Wegener’s granulomatosis: a clinicopathologic study of 17 patients and
correlation to antineutrophil cytoplasmic antibody status. J Cutan Pathol.
(2007) 34:739–47. doi: 10.1111/j.1600-0560.2006.00699.x
4. Postow MA, Hellmann MD. Adverse events associated with
immune checkpoint blockade. N Engl J Med. (2018) 378:1165.
doi: 10.1056/NEJMc1801663
5. Brahmer J, Reckamp KL, Baas P, Crinò L, EberhardtWE, Poddubskaya E, et al.
Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung
cancer. N Engl J Med. (2015) 373:123–35. doi: 10.1056/NEJMoa1504627
6. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung
cancer. N Engl J Med. (2015) 373:1627–39. doi: 10.1056/NEJMoa1507643
7. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY,
et al. Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-
010): a randomised controlled trial. Lancet. (2016) 387:1540–50.
doi: 10.1016/S0140-6736(15)01281-7
8. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel
J, et al. Atezolizumab versus docetaxel in patients with previously
treated non-small-cell lung cancer (OAK): a phase 3, open-label,
multicentre randomised controlled trial. Lancet. (2017) 389:255–65.
doi: 10.1016/S0140-6736(16)32517-X
9. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al.
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung
cancer. N Engl J Med. (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774
10. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al.
Management of toxicities from immunotherapy: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017)
28(Suppl_4):iv119–42. doi: 10.1093/annonc/mdx225
11. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R,
et al. Association of immune-related adverse events with nivolumab
efficacy in non-small cell lung cancer. JAMA Oncol. (2018) 4:374–8.
doi: 10.1001/jamaoncol.2017.2925
12. Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, et al.
Characterization of nivolumab-associated skin reactions in patients with
metastatic non-small cell lung cancer. Oncoimmunology. (2016) 5:e1231292.
doi: 10.1080/2162402X.2016.1231292
13. Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al.
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade
in patients with non-small-cell lung cancer. Ann Oncol. (2017) 28:583–9.
doi: 10.1093/annonc/mdw640
14. Cui J, Bystryn JC. Melanoma and vitiligo are associated with antibody
responses to similar antigens on pigment cells. Arch Dermatol. (1995)
131:314–8. doi: 10.1001/archderm.131.3.314
15. Yoest JM. Clinical features, predictive correlates, and pathophysiology
of immune-related adverse events in immune checkpoint inhibitor
treatments in cancer: a short review. Immunotar Ther. (2017) 6:73–82.
doi: 10.2147/ITT.S126227
16. Zhang M, Xia L, Yang Y, Liu S, Ji P, Wang S, et al. PD-1 blockade augments
humoral immunity through ICOS-mediated CD4. Int Immunopharmacol.
(2019) 66:127–38. doi: 10.1016/j.intimp.2018.10.045
17. Nishino M, Sholl LM, AwadMM, Hatabu H, Armand P, Hodi FS. Sarcoid-like
granulomatosis of the lung related to immune-checkpoint inhibitors: distinct
clinical and imaging features of a unique immune-related adverse event.
Cancer Immunol Res. (2018) 6:630–5. doi: 10.1158/2326-6066.CIR-17-0715
18. Faviez G, Bousquet E, Rabeau A, Rouquette I, Collot S, Goumarre
C, et al. Sarcoid-like granulomatosis in cancer patients treated with
immune checkpoints inhibitors. Rev Mal Respir. (2018) 35:963–7.
doi: 10.1016/j.rmr.2018.08.003
19. van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal
C, de Groot DJ, et al. Rapid granulomatosis with polyangiitis induced
by immune checkpoint inhibition. Rheumatology. (2016) 55:1143–5.
doi: 10.1093/rheumatology/kew063
20. Wilde B, Hua F, Dolff S, Jun C, Cai X, Specker C, et al. Aberrant expression of
the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis.
Rheumatology. (2012) 51:1188–97. doi: 10.1093/rheumatology/kes034
21. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al.
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J
Transl Med. (2009) 7:35. doi: 10.1186/1479-5876-7-35
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Sibille, Alfieri, Malaise, Detrembleur, Pirotte, Louis and Duysinx.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Oncology | www.frontiersin.org 4 June 2019 | Volume 9 | Article 478
